The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 9 rounds in the feed, most often in Biotech.
dimensioncap.comRounds from 2024-11-21 to 2026-09-23
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Enveda Biosciences A clinical-stage biotechnology company that uses AI to discover medicines from life's chemistry | Series E Verified against 4 of 37 sources | $311M | 2026-09-23 | [ PART ] |
Chai Discovery A company that develops AI models that predict and reprogram the interactions between molecules | Series C |
| $400M |
| 2026-07-14 |
| [ PART ] |
Chai Discovery A company that develops AI models that predict and reprogram the interactions between molecules | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2025-12-14 | [ PART ] |
Odyssey Odyssey Therapeutics develops innovative therapies aimed at transforming the treatment of autoimmune and inflammatory diseases for patients. | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $213M | 2025-09-10 | [ PART ] |
Enveda Biosciences A clinical-stage biotechnology company that uses AI to discover medicines from life's chemistry | Series D Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-09-04 | [ PART ] |
Chai Discovery A company that develops AI models that predict and reprogram the interactions between molecules | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2025-08-06 | [ PART ] |
NewLimit NewLimit is extending human healthspan by unlocking regenerative potential., | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2025-05-06 | [ PART ] |
Aspect Biosystems Bioengineered cellular medicines aimed at transforming disease treatment using bioprinting technology and regenerative medicine. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-01-08 | [ LEAD ] |
Enveda Biosciences A clinical-stage biotechnology company that uses AI to discover medicines from life's chemistry | Series C Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2024-11-21 | [ PART ] |